Organogenesis Holdings Inc
NASDAQ:ORGO

Watchlist Manager
Organogenesis Holdings Inc Logo
Organogenesis Holdings Inc
NASDAQ:ORGO
Watchlist
Price: 3.05 USD -1.93% Market Closed
Market Cap: 404.4m USD
Have any thoughts about
Organogenesis Holdings Inc?
Write Note

Gross Margin
Organogenesis Holdings Inc

75.3%
Current
76%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
75.3%
=
Gross Profit
342.6m
/
Revenue
455m

Gross Margin Across Competitors

Country US
Market Cap 404.4m USD
Gross Margin
75%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.3B USD
Gross Margin
67%
Country US
Market Cap 141.6B USD
Gross Margin
60%
Country US
Market Cap 115.3B USD
Gross Margin
78%
Country US
Market Cap 102.4B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 77.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 35.7B EUR
Gross Margin
89%
No Stocks Found

Organogenesis Holdings Inc
Glance View

Market Cap
404.4m USD
Industry
Biotechnology

Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.

ORGO Intrinsic Value
3.4 USD
Undervaluation 10%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
75.3%
=
Gross Profit
342.6m
/
Revenue
455m
What is the Gross Margin of Organogenesis Holdings Inc?

Based on Organogenesis Holdings Inc's most recent financial statements, the company has Gross Margin of 75.3%.